Unknown

Dataset Information

0

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study.

ABSTRACT:

SUBMITTER: Torres T 

PROVIDER: S-EPMC12936243 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada.
| S-EPMC11979299 | biostudies-literature
Unknown Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
| S-EPMC9287013 | biostudies-literature
Unknown Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT.
| S-EPMC10087575 | biostudies-literature
Unknown Tildrakizumab in Managing Psoriasis with Involvement of Difficult-to-Treat Areas: A Multicenter Real-Life Retrospective Study.
| S-EPMC12841847 | biostudies-literature
Unknown Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.
| S-EPMC12936322 | biostudies-literature
Unknown Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
| S-EPMC9442573 | biostudies-literature
Unknown Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.
| S-EPMC10954292 | biostudies-literature
Unknown Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.
| S-EPMC9209594 | biostudies-literature
Unknown Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
| S-EPMC9287038 | biostudies-literature
Unknown Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
| S-EPMC11484122 | biostudies-literature